Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-006 trial of M-Pa-Z versus standard tuberculosis therapy
PACTR201408000858108Suspended
- Sponsor
- TB Alliance
- Start
- Nov 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Randomised trial of moxifloxacin, pretomanid, pyrazinamide, isoniazid, rifampicin and 1 more in Tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) (4 arms), sponsored by TB Alliance. Primary endpoint: Incidence of bacteriologic failure, relapse, or clinical failure. Started Nov 2014; status: suspended.
02
Drugs
moxifloxacinpretomanidpyrazinamideisoniazidrifampicin
03
Conditions
Tuberculosis (TB)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on PACTR201408000858108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201408000858108.